Ibrutinib may afford better overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) in patients with relapsed or refractory chronic lymphocytic leukaemia (R/R CLL) compared with ofatumumab, the idelalisib-ofatumumab combination and physician’s choice, according to a systematic literature review.
Botulinum toxin is as good as surgery for treating acute-onset, comitant esotropia at 6 months in children, with the advantage of reducing general anaesthesia duration and healthcare costs, according to a small study.
MIMS sat down with Krister Eunice Basbas Padilla, one of the first SPC-recognised Filipino pharmacists in Singapore, to talk about what she has learned from working in the Lion City, and what she thinks can help improve the pharmacy profession in the Philippines.
A percutaneous gastrostomy device, the AspireAssist System, in conjunction with lifestyle counselling is more effective in inducing weight loss in individuals with Class II and III obesity than lifestyle counselling alone, according to the PATHWAY* study.
Administering proton pump inhibitor (PPI) prior to endoscopic submucosal dissection (ESD) for differentiated early gastric cancer with ulcer may effectively heal the ulcer lesion and shorten the mean procedure time, according to a study.
There is an independent association between positive clinical trial results and financial ties of principal investigators, which may be suggestive of bias in the evidence base, according to the results of a cross-sectional study of randomized controlled trials (RCTs).
Therapeutic drug monitoring of anti-tumour necrosis factor (TNF) may yield substantial savings in the costs of both inflammatory bowel disease and rheumatoid arthritis, without any negative effect on efficacy, according to the results of a systematic review.
Cyclin-dependent kinase (CDK) 4/6 inhibitors may be a potential game changer in breast cancer therapy, with promising results from the MONALEESA-2 trial sub-analysis showing that ribociclib, in combination with letrozole, significantly improved progression-free survival (PFS) in Asian women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer.
The use of certain systemic medications may influence intraocular pressure (IOP), and potentially, glaucoma risk, according to a post hoc analysis of the SEED* study.
The standard-dose combination of calcium channel blocker (CCB) plus angiotensin receptor blocker (ARB) appears to provide better blood pressure (BP)-lowering benefits in hypertensive patients compared with high-dose CCB monotherapy, with the added advantage of lower adverse event rate, according to the results of a meta-analysis.